trientine tetrahydrochloride · Orphalan · NDA 215760
Cuvrior
Earliest generic entry, as listed
3 May 2039
Blocked by patent: US 10988436, US 11072577, US 12358861, US 12358862, US 12662445.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10988436 | substance | 3 May 2039 |
| US 11072577 | use U-3370 | 3 May 2039 |
| US 12358861 | substance, product, use U-4262 | 3 May 2039 |
| US 12358862 | substance, product, use U-4262 | 3 May 2039 |
| US 12662445 | substance, product, use U-4262 | 3 May 2039 |
Exclusivities · 1 unexpired
| ODE-401 | orphan drug (7 years) | 28 Apr 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215760 · 001 · RLD | tablet, oral | 300MG | 3 May 2039 |